Ting Li
Xi'an Jiaotong University
6 Papers
10 Citations
Ting Li is an academic researcher from Xi'an Jiaotong University. The author has contributed to research in topics: Tumor progression & Medicine. The author has an hindex of 5, co-authored 6 publications.
Chat about Author
Papers
Precision medicine for hepatocellular carcinoma: driver mutations and targeted therapy
Xiao-Xiao Ding,Qing-Ge Zhu,Shi-Ming Zhang,Lei Guan,Ting Li,Lei Zhang,Shiyang Wang,Wanli Ren,Xue-Mei Chen,Jing Zhao,Song Lin,Zhi-Zhen Liu,Yanxia Bai,Bing He,Hu-Qin Zhang +14 more
TL;DR: This review summarized currently discovered driver mutations and corresponding signaling pathways, made an overview of identification methods ofDriver mutations and genes, and classified targeted drugs for HCC.
88
CTNNA3 is a tumor suppressor in hepatocellular carcinomas and is inhibited by miR-425
Bing He,Ting Li,Lei Guan,Fang-E Liu,Xue-Mei Chen,Jing Zhao,Song Lin,Zhi-Zhen Liu,Hu-Qin Zhang +8 more
TL;DR: The tumor suppressor function of CTNNA3 and the oncogenic function of miR-425 were further confirmed in HCC cell xenograft in nude mice and may provide insights into the mechanisms underlying HCC, and contribute to potential therapeutic strategy of HCC.
Identifying key regulating miRNAs in hepatocellular carcinomas by an omics' method.
Bing He,Peng Lu,Lei Guan,Ting Li,Lei Zhang,Qing-Ge Zhu,Xiao-Xiao Ding,Shi-Ming Zhang,Xue-Mei Chen,Jing Zhao,Song Lin,Zhi-Zhen Liu,Fang-E Liu,Wang Ma,Hu-Qin Zhang +14 more
TL;DR: Investigations indicated that miR-590-3P play its roles by inhibiting polycomb protein EED and revealed the MNBO would be a useful strategy to uncover key regulating miRNAs in HCC.
10
Downregulation of TMEM220 promotes tumor progression in Hepatocellular Carcinoma.
Ting Li,Lei Guan,Guangbo Tang,Bing He,Lili Huang,Juan Wang,Mingyue Li,Yanxia Bai,Xinyuan Li,Hu-Qin Zhang +9 more
TL;DR: This study proposes a working model in which upregulation of TMEM220 expression alters the genes expression involved in cell proliferation, thereby inhibiting HCC progression, which suggests that TMEM 220 might serve as a clinical biomarker.
MEIS2C and MEIS2D promote tumor progression via Wnt/β-catenin and hippo/YAP signaling in hepatocellular carcinoma
Lei Guan,Ting Li,Nanping Ai,Wei Wang,Bing He,Bing He,Yanxia Bai,Zhaocai Yu,Mingyue Li,Shan-Shan Dong,Qing-Ge Zhu,Xiao Xiao Ding,Shi-Ming Zhang,Ming li,Guangbo Tang,Xiaochun Xia,Jing Zhao,Song Lin,Shi yao,Lei Zhang,Geng chen,Fang-E Liu,Xinyuan Li,Hu-Qin Zhang +23 more
TL;DR: The studies indicate that MEISC/D promote HCC development via Wnt/β-catenin and Hippo/YAP signaling pathways, highlighting the complex molecular network of MEIS2C/D in HCC pathogenesis and suggest that MEIS/D may serve as a potential novel therapeutic target for HCC.